ASH 2018: Kipps on Venetoclax Outcomes Including Resistance—The “Whack a Mole” Challenge By Larry Marion Part one of two. Part two will be continued next week. Resistance is the scariest word in the English... April 21, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Professor Hillmen on Venetoclax Resistance in CLL By Brian Koffman, MD ASH 2018: Professor Hillmen on Venetoclax Resistance in CLL (chronic lymphocytic leukemia) On the last day of ASH... December 14, 20182018 ConferencesBy Brad Hedrick
ASH 2017: Dr. Adrian Wiestner on Resistance Mechanism in CLL (chronic lymphocytic leukemia) I had the opportunity to interview Dr. Adrian Wiestner from the National Institutes of Health at ASH 2017 in Atlanta GA about... July 30, 20182017 ConferencesBy Brian Koffman
ASH 2017: Professor Michael Hallek on Molecular Evolution in CLL and Venetoclax Resistance At the ASH (American Society of Hematology) annual meeting in 2017 held in Atlanta, GA, I had the opportunity to... June 12, 20182017 ConferencesBy Todd Dennison
ASH 2016: An Interview with Dr. George Follows on Late Resistance to Ibrutinib in CLL At ASH 2016 Dr. George Follows of Cambridge, England discusses our evolving understanding of life after ibrutinib for those of... June 27, 20172016 Conferences, Conference CoverageBy Brian Koffman
Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia Ibrutinib works amazingly well for most CLL patient by blocking BTK (Bruton’s tyrosine kinase), an enzyme that is overactive in... April 18, 2017TreatmentBy Todd Dennison
ASH 2016: Dr. Neil Kay: Mechanism of Ibrutinib’s Resistance in CLL In San Diego in December 2016 at the annual American Society of Hematology ASH) meeting, I interviewed Dr. Neil Kay... February 21, 20172016 ConferencesBy Todd Dennison
ASH 2015: Dr. Stephan Stilgenbauer on Resistance to Ibrutinib in CLL In the second part of three interviews from the 2015 American Society of Hematology annual meeting with Dr. Stephan Stilgenbauer... March 6, 20162015 ConferencesBy Todd Dennison
CRC 2015: Ibrutinib Resistance, Drug Combos, and Treating Asymptomatic CLL In our wide-ranging interview from the CRC (Chronic Lymphocytic Leukemia Research Consortium) meeting in April 2015, we look at how... October 19, 20152015 ConferencesBy Todd Dennison
ASH 2014: Dr. Jan Burger on Ibrutinib Resistance in CLL Dr. Jan Burger from the MD Anderson Cancer Center spoke to me about his research on ibrutinib resistance in chronic... May 18, 20152014 ConferencesBy Todd Dennison
